Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...
The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...
Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...
Techno-Science.net on MSN
A method to produce anti-cancer killer cells en masse
Natural killer cells, or NK cells, are elements of the immune system capable of rapidly locating and destroying cancerous or ...
Manufacturing time and cost create two of the biggest challenges to making cell therapies available to more patients. Scientists at San Diego-based Artiva Biotherapeutics hope to change that with ...
Each immune cell group has distinct metabolic requirements, activation pathways, and cytokine reliance. Standard, one-size-fits-all media cannot address these features. When studying diverse cell ...
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...
Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across ...
News Medical on MSN
Lund researchers create "recipe book" for reprogramming immune cells to fight disease
In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback